Herpes simplex virus hepatitis in mice: effects of treatment with trisodium phosphonoformate.
- Published Article
- Publication Date
Dec 01, 1985
Clinical isolates of herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) induced focal necrotic hepatitis in ICR/Schö mice. The extent of the hepatitis could be considerably reduced by trisodium phosphonoformate (PFA) administered for 3 days in a daily dose of 400-600 mg/kg. The HSV hepatitis in mice could serve as a suitable model for testing antiherpetic drugs.
Report this publication
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
This record was last updated on 07/02/2016 and may not reflect the most current and accurate biomedical/scientific data available from NLM.
The corresponding record at NLM can be accessed at https://www.ncbi.nlm.nih.gov/pubmed/2869661